近年来发表的主要论著:
1). LuCC, Hu ZB, Wang R, Hong ZH, Lu J, Chen PP, Zhang JX, Li XQ, Yuan BY, Huang SJ,Ruan XZ, Liu BC, Ma KL(*). Gut microbiota dysbiosis-inducedactivation of the intrarenal renin-angiotensin system is involved in kidneyinjuries in rat diabetic nephropathy. Acta Pharmacol Sin 2020 Mar 17. doi:10.1038/s41401-019-0326-5. [Epub ahead of print]. (IF=4.01).
2). Hu ZB, Lu J, Chen PP, Lu CC, Zhang JX, Li XQ, YuanBY, Huang SJ, Ruan XZ, Liu BC, Ma KL(*). Dysbiosis of intestinal microbiota mediatestubulointerstitial injury in diabetic nephropathy via the disruption ofcholesterol homeostasis. Theranostics 2020;10(6):2803-2816. (IF=8.063).
3) Lu J, Hu ZB, Chen PP, Lu CC, Zhang JX, Li XQ, Yuan BY, Huang SJ, *MaKL. Urinary levels of podocyte-derived microparticles are associated withthe progression of chronic kidney disease. Ann Transl Med. 2019 Sep;7(18):445. (IF=3.689).
4) Lu J, Hu ZB, Chen PP, Lu CC, Zhang JX, Li XQ, Yuan BY, Huang SJ, *MaKL. Urinary podocyte microparticles are associated with disease activityand renal injury in systemic lupus erythematosus. BMC Nephrol. 2019 Aug5;20(1):303. (IF=2.088).
5). *Ma KL, Liu L, Zhang Y, Wang GH, Hu ZB, Chen PP, Lu J, Lu CC,Gong TK, Gong YX, Liu BC. Aspirin attenuates podocyte injury in diabetic ratsthrough overriding cyclooxygenase-2-mediated dysregulation of LDL receptorpathway. Int Urol Nephrol. 2019 Mar;51(3):551-558. (IF=1.596)
6). Wang GH, *Ma KL, Zhang Y, Hu ZB, Liu L, Lu J, Chen PP, Lu CC,Ruan XZ, Liu BC. Caspase 3/ROCK1 pathway mediates high glucose-induced plateletmicroparticles shedding. Biochem Biophys Res Commun. 2019 Feb 5;509(2):596-602.(IF=2.705)
7). Wang GH, *Ma KL, Zhang Y, Hu ZB, Liu L, Lu J, Chen PP, Lu CC, Ruan XZ, LiuBC. Platelet microparticles contribute to aorticvascular endothelial injury in diabetes via the mTORC1 pathway. Acta Pharmacol Sin. 2019Apr;40(4):468-476. (IF=4.01).
8) Wang GH, Lu J, *Ma KL, ZhangY, Hu ZB, Chen PP, Lu CC, Zhang XL, Liu BC. TheRelease of Monocyte-Derived Tissue Factor-Positive Microparticles Contributesto a Hypercoagulable State in Idiopathic Membranous Nephropathy. J Atheroscler Thromb. 2019Jun 1;26(6):538-546. (IF=3.478).
9) Zhang Y, *Ma KL, Gong YX,Wang GH, Hu ZB, Liu L, Lu J, Chen PP, Lu CC, Ruan XZ, Liu BC. Platelet Microparticles Mediate Glomerular Endothelial Injury in EarlyDiabetic Nephropathy. J Am Soc Nephrol. 2018;29(11):2671-2695.(IF=8.547).
10). *Ma KL, GongTK, Hu ZB, Zhang Y, Wang GH, Liu L, Chen PP, Lu J, Lu CC, Liu BC.Lipoprotein(a) accelerated the progression of atherosclerosis in patients withend-stage renal disease. BMC Nephrol. 2018;19(1):192. (IF=2.088).
11) *Ma KL, Wu Y, Zhang Y, Wang GH, Hu ZB,Ruan XZ. Activation of the CXCL16/CXCR6 pathway promotes lipid deposition infatty livers of apolipoprotein E knockout mice and HepG2 cells. Am J TranslRes. 2018;10(6):1802-1816. (IF=3.266).
12) Lu CC, *Ma KL, Ruan XZ, Liu BC. Intestinal dysbiosis activatesrenal renin-angiotensin system contributing to incipient diabetic nephropathy.Int J Med Sci. 2018;15(8):816-822. (IF=2.333).
13) Hu ZB, *Ma KL, Zhang Y, Wang GH, Liu L, Lu J, Chen PP, Lu CC,Liu BC. Inflammation-activated CXCL16 pathway contributes to tubulointerstitialinjury in mouse diabetic nephropathy. Acta Pharmacol Sin. 2018;39(6):1022-1033.(IF=4.01).
14) Lu CC, *Ma KL, Ruan XZ, Liu BC. The Emerging Roles ofMicroparticles in Diabetic Nephropathy. Int J Biol Sci. 2017 Sep5;13(9):1118-1125. (IF=4.067).
15). #Hu ZB, #Chen Y, Gong YX, Gao M, Zhang Y, Wang GH, Tang RN, Liu H, LiuBC, *Ma KL. Activation of theCXCL16/CXCR6 Pathway by Inflammation Contributes to Atherosclerosis in Patientswith End-stage Renal Disease. Int J Med Sci.2016;13(11):858-867. (IF=2.333).
16）WuY, *Ma KL, Zhang Y, Wen Y, Wang GH, Hu ZB, Liu L, Lu J, Chen PP, RuanXZ, Liu BC. Lipid disorder and intrahepatic renin-angiotensin system activationsynergistically contributes to non-alcoholic fatty liver disease. Liver Int. 2016;36(10):1525-34.（IF=5.542）
17）ZhangY, *Ma KL, Ruan XZ, Liu BC. Dysregulation of the Low-Density LipoproteinReceptor Pathway Is Involved in Lipid Disorder-Mediated Organ Injury. Int JBiol Sci. 2016; 12(5):569-79. (IF=4.067)
18). *Ma KL, Zhang Y, Liu J, Wu Y, Hu ZB,Liu L, Liu BC. Inflammatory stress induces lipid accumulation in multi-organsof db/db mice. Acta Biochim Biophys Sin (Shanghai). 2015; 47(10): 767-74. (IF=2.502).
, Liu J, Wu Y, Hu ZB, Liu L, Lu J, Zhang XL, LiuBC. Inflammatory stress exacerbates lipid accumulation and podocyte injuries indiabetic nephropathy. Acta Diabetol. 2015; 52(6):1045-56. (IF=2.996).
21).Liu J, *Ma KL, Zhang Y, Wu Y, Hu ZB, Lv LL, Tang RN, Liu H, Ruan XZ, LiuBC. Activation of mTORC1disrupted LDL receptor pathway: a potential new mechanism for the progressionof non-alcoholic fatty liver disease. Int J Biochem Cell Biol. 2015; 61:8-19.(IF=3.144)
22). *Ma KL, Zhang Y,Liu J, Wu Y, Hu ZB, Ruan XZ, Liu BC. Establishment of an Inflamed Animal Modelof Diabetic Nephropathy. Int J Biol Sci 2014; 10(2):149-159.(IF=4.067)
23). Ma KL,LiuJ, Gao M, Wang CX, Ni J, Zhang Y,Zhang XL, Liu H, Wang YL, *Liu BC. Activation of mTOR contributes to foam cell formation in the radialarteries of patients with end-stage renal disease. ClinNephrol. 2014; 81(6)：396-404.（IF=1.079）
24). Ma KL, Ni J,Wang CX, Liu J, Zhang Y, Wu Y, Lv LL, Ruan XZ, *Liu BC. Interaction of RASActivation and Lipid Disorders Accelerates the Progression ofGlomerulosclerosis. Int JMed Sci 2013; 10(12):1615-24. (IF=2.333)
25). Ma KL, Liu J,Wang CX, Ni J, Zhang Y, Wu Y, Lv LL, Ruan XZ, Liu BC. Activation of mTORmodulates SREBP-2 to induce foam cell formation through increasedretinoblastoma protein phosphorylation. Cardiovasc Res 2013; 100(3):450-60. (IF=7.014).
26). Ni J, *Ma KL,Wang CX, Liu J, Zhang Y, Lv LL, Ni HF, Chen YX, Ruan XZ, Liu BC. Activation ofrenin-angiotensin system is involved in dyslipidemia-mediated renal injuries inapolipoprotein E knockout mice and HK-2 cells. Lipids Health Dis 2013; 12(1):49. (IF=2.651).
27). Ma KL, Liu J, NiJ, Zhang Y, Lv LL, Tang RN, Ni HF, Ruan XZ, *Liu BC. Inflammatory stressexacerbates the progression of cardiac fibrosis in high-fat-fed apolipoproteinE knockout mice via endothelial-mesenchymal transition. Int JMed Sci 2013; 10(4):420-6. (IF=2.333).
28). *Ma KL, Wang CX.Analysis of the spectrum and antibiotic resistance of uropathogens in vitro:results based on a retrospective study from a tertiary hospital. Am J Infect Control2013; 41(7):601-6. (IF=1.971)
29). Liu J, *Ma KL,Gao M, Wang CX, Ni J, Zhang Y, Zhang XL, Liu H, Wang YL, Liu BC. Inflammationdisrupts the LDL receptor pathway and accelerates the progression of vascularcalcification in ESRD patients. PLoS One 2012;7(10):e47217.(IF=2.776).
30). Ma KL, VargheseZ, Ku Y, Powis SH, Chen Y, Moorhead JF, *Ruan XZ. Sirolimus inhibits endogenouscholesterol synthesis induced by inflammatory stress in human vascular smoothmuscle cells. Am J Physiol Heart Circ Physiol 2010; 298(6):H1646-51.(IF=4.048).
31). Ma KL, *RuanXZ, Powis SH, Chen YX, Moorhead JF, andVarghese Z. Inflammatory stress exacerbates lipid accumulation in hepatic cellsand fatty livers of apolipoprotein E knockout mice. Hepatology 2008; 48 (3):770-81. (IF=14.971).
32). Ma KL, *Ruan XZ, Powis SH, Chen Y, Moorhead JF, Varghese Z. Sirolimus modifies cholesterolhomeostasis in hepatic cells: a potential molecular mechanism forsirolimus-associated dyslipidemia. Transplantation 2007; 84(8):1029-36.(IF=4.593).
33). Ma KL, *Ruan XZ, Powis SH, Moorhead JF,and Varghese Z. Anti-atherosclerotic effects of sirolimus on human vascularsmooth muscle cells. Am J Physiol Heart Circ Physiol 2007; 292 (6):H2721-8.(IF=4.048).